Kaijian Lei

机构：Second People’s Hospital of Yibin, Shanghai Maritime University · ORCID：0000-0002-2008-3726

发表论文 68 篇 · 总被引 564 次 · h-index 14

代表论文

• Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 20)
• Synergistic strategies in photodynamic combination therapy for cancer: mechanisms, nanotechnology, and clinical translation (2025 · Frontiers in Oncology · 被引 17)
• SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial. (2024 · Journal of Clinical Oncology · 被引 16)
• 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma (2023 · Annals of Oncology · 被引 12)
• Research progress on the role of PTEN deletion or mutation in the immune microenvironment of glioblastoma (2024 · Frontiers in Oncology · 被引 9)
• Single‐photon emission computed tomography‐defined active bone marrow‐sparing volumetric‐modulated arc therapy reduces the incidence of acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy: A single‐center prospective randomized controlled trial (2023 · Cancer · 被引 8)